ADC Therapeutics SA Quick Ratio 2019-2022 | ADCT

Historical quick ratio values for ADC Therapeutics SA (ADCT) over the last 10 years.
ADC Therapeutics SA Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2022-12-31 $0.43B $0.10B 4.32
2022-09-30 $0.42B $0.09B 4.82
2022-06-30 $0.41B $0.07B 5.56
2022-03-31 $0.48B $0.07B 6.72
2021-12-31 $0.51B $0.07B 6.95
2021-09-30 $0.56B $0.06B 9.45
2021-06-30 $0.39B $0.05B 7.51
2021-03-31 $0.00B $0.04B 0.00
2020-12-31 $0.00B $0.04B 0.00
2020-09-30 $0.00B $0.03B 0.00
2020-06-30 $0.00B $0.03B 0.00
2020-03-31 $0.00B 0.00
2019-12-31 $0.00B 0.00
2019-09-30 $0.00B 0.00
2019-06-30 $0.00B 0.00
2018-12-31 $0.00B $0.02B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.153B $0.210B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.122B 8.73
GSK (GSK) United Kingdom $75.233B 9.43
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.461B 19.38
Ginkgo Bioworks Holdings (DNA) United States $2.529B 0.00
Arcus Biosciences (RCUS) United States $1.165B 0.00
Biohaven (BHVN) United States $0.882B 0.00
Emergent Biosolutions (EBS) United States $0.391B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00
Gelesis Holdings (GLS) United States $0.011B 0.00